<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="101985"><DrugName>DSP-1200</DrugName><DrugSynonyms><Name><Value>DSP-1200</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1017117">Sumitomo Dainippon Pharma Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1017117" type="Company"><TargetEntity id="4295877685" type="organizationId">Sumitomo Dainippon Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="6921" type="Action"><TargetEntity id="41" type="Mechanism">alpha2A(2D)-Adrenoceptor Antagonists</TargetEntity><TargetEntity id="2165" type="Mechanism">alpha2A(2D)-Adrenoceptor Inverse Agonists</TargetEntity></SourceEntity><SourceEntity id="585" type="Action"><TargetEntity id="210" type="Mechanism">5-HT2A Antagonists</TargetEntity></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00019" type="ciTarget"><TargetEntity id="177095838133563" type="siTarget">5-hydroxytryptamine receptor 2A</TargetEntity><TargetEntity id="-1907037521" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00109" type="ciTarget"><TargetEntity id="19513068371503" type="siTarget">Alpha-2A adrenergic receptor</TargetEntity><TargetEntity id="-2106175457" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00633" type="ciTarget"><TargetEntity id="80088336218133" type="siTarget">D(2) dopamine receptor</TargetEntity><TargetEntity id="8168" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="150">Dopamine D2 receptor antagonist</Action><Action id="585">5-HT 2a receptor antagonist</Action><Action id="6921">Alpha 2A adrenoceptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="284">Nootropic agent</Action><Action id="2941">Antidepressant</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-01T13:40:46.000Z</LastModificationDate><ChangeDateLast>2017-11-06T00:00:00.000Z</ChangeDateLast><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1017117" linkType="Company"&gt;Sumitomo Dainippon&lt;/ulink&gt; was developing DSP-1200, an antagonist of dopamine D2, serotonin 5-HT2A and adrenergic alpha 2A receptors, which is expected to enhance acetylcholine, dopamine, and noradrenaline release in the prefrontal cortex and improve depressive symptoms and cognitive function, for the potential oral treatment of treatment-resistant depression (TRD). By May 2016, a phase I study for TRD had started in the US [&lt;ulink linkID="1761015" linkType="Reference"&gt;1761015&lt;/ulink&gt;]. In October 2017, the company reported that development of DSP-1200 had been discontinued [&lt;ulink linkID="1976837" linkType="Reference"&gt;1976837&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By May 2016, DSP-1200 was in phase I development for TRD in the US [&lt;ulink linkID="1761015" linkType="Reference"&gt;1761015&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;DSP-1200 has low or negligible affinities for receptors associated with safety issues [&lt;ulink linkID="1761015" linkType="Reference"&gt;1761015&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2017-10-30T00:00:00.000Z</StatusDate><Source id="1976837" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2016-05-11T00:00:00.000Z</StatusDate><Source id="1761015" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00019"><Name>5-HT 2a receptor</Name><SwissprotNumbers><Swissprot>O46635</Swissprot><Swissprot>P14842</Swissprot><Swissprot>P18599</Swissprot><Swissprot>P28223</Swissprot><Swissprot>P28285</Swissprot><Swissprot>P35363</Swissprot><Swissprot>P35382</Swissprot><Swissprot>P50128</Swissprot><Swissprot>P50129</Swissprot><Swissprot>Q5R4Q6</Swissprot><Swissprot>Q75Z89</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00109"><Name>Alpha 2A adrenoceptor</Name><SwissprotNumbers><Swissprot>Q90WY4</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00633"><Name>Dopamine D2 receptor</Name><SwissprotNumbers><Swissprot>O73810</Swissprot><Swissprot>P14416</Swissprot><Swissprot>P20288</Swissprot><Swissprot>P52702</Swissprot><Swissprot>P60026</Swissprot><Swissprot>P61168</Swissprot><Swissprot>P61169</Swissprot><Swissprot>Q9GJU1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1976837" linkType="reference" linkID="1976837"&gt;1976837&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>